نتایج جستجو برای: sustained virological responses

تعداد نتایج: 476190  

Journal: :Arquivos de gastroenterologia 2010
Vasileios Papadopoulos Aikaterini Gogou Theodora Mylopoulou Konstantinos Mimidis

CONTEXT Accumulating data propose that active injecting drug users might not differ from the general population in terms of sustained virological response when adherent to therapy for chronic hepatitis C. However, current guidelines contain restrictive recommendations for therapy in this group of patients. OBJECTIVE Therefore, we evaluated a cohort of chronic hepatitis C patients regarding th...

Journal: :Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 2016
Ruby Ann Chirino-Sprung Margarita Dehesa Enrique Wolpert Clara Corona-Lau Ignacio García-Juarez José Francisco Sánchez-Ávila Carlos Moctezuma-Velázquez David Kershenobich

BACKGROUND In clinical trials, new oral direct-acting antiviral agent therapies have demonstrated a high sustained virological response rate in patients with hepatitis C virus infection. We aimed to analyze the efficacy and safety data from direct-acting antiviral agent interferon-free therapy in hepatitis C virus infection in a study performed in five different clinical settings in Mexico City...

Journal: :Journal of hepatology 2016
Håvard Midgard Benedikte Bjøro Arild Mæland Zbigniew Konopski Hege Kileng Jan K Damås Jørn Paulsen Lars Heggelund Per K Sandvei Jetmund O Ringstad Lars N Karlsen Kathrine Stene-Johansen John H-O Pettersson Dagny H Dorenberg Olav Dalgard

BACKGROUND & AIMS On-going risk behaviour can lead to hepatitis C virus (HCV) reinfection following successful treatment. We aimed to assess the incidence of persistent HCV reinfection in a population of people who inject drugs (PWID) who had achieved sustained virological response (SVR) seven years earlier. METHODS In 2004-2006 we conducted a multicentre treatment trial comprising HCV genoty...

2015
Frédégonde About Tiphaine Oudot-Mellakh Jonathan Niay Pascaline Rabiéga Vincent Pedergnana Darragh Duffy Philippe Sultanik Carole Cagnot Fabrice Carrat Patrick Marcellin Fabien Zoulim Dominique Larrey Christophe Hézode Hélène Fontaine Jean-Pierre Bronowicki Stanislas Pol Matthew L. Albert Ioannis Theodorou Aurélie Cobat Laurent Abel Chen-Hua Liu

BACKGROUND Human genetic factors influence the outcome of pegylated interferon and ribavirin hepatitis C therapy. We explored the role of IL28B, APOH and ITPA SNPs on the outcomes of triple therapy including telaprevir or boceprevir in patients with compensated cirrhosis chronically infected with HCV-1. PATIENTS AND METHODS A total of 256 HCV-1 Caucasian treatment-experienced patients with co...

2014
Alessandra Mangia Giovanni Cenderello Alessandra Orlandini Valeria Piazzolla Antonio Picciotto Massimo Zuin Alessia Ciancio Giuseppina Brancaccio Paolo Forte Vito Carretta Anna Linda Zignego Nicola Minerva Gaetano Brindicci Massimo Marignani Gianluca Svegliati Baroni Gaetano Bertino Giuseppe Cuccorese Leonardo Mottola Maria Ripoli Mario Pirisi Giovanni Li Volti

BACKGROUND Triple therapy including Telaprevir or Boceprevir still represents in many European countries the standard of care for patients with Hepatitis C Virus genotype 1 infection. The number of patients who received this treatment resulted generally lower than expected. We investigated, among naïve patients, number and characteristics of treatment candidates who were started on triple or du...

Journal: :Journal of medical virology 2011
F Nicot L Alric K Barange S Métivier J M Dramard J M Combis B Castan J J Meurisse J L Payen D Garipuy H Desmorat J M Peron S Thebault T Morin C Renou P Barel B Guerin Y Imbert S Sire K Sauné E Chatelut J Izopet

New factors that influence the viral response in HCV non-genotype 2/3 patients must be identified in order to optimize anti-HCV treatment. This multicenter prospective study evaluates the influence of HCV variability and pharmacological parameters on the virological response of these patients to pegylated interferon α2a (peg-IFN-α2a: 180 µg/week) and ribavirin (RBV; 800-1,200 mg/day) for 48 wee...

Journal: :The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2004
Antonio Alci Barone Rose Aparecida Borges Tosta Fátima Mitiko Tengan José Humberto Caetano Marins Norma de Paula Cavalheiro Bruno Andrade Cardi

A follow-up study was made of 94 chronic hepatitis C patients at a hepatitis clinic in Brazil, after interferon alpha (IFN-alpha) therapy, to determine the influence of anti-interferon antibodies on treatment outcome. Patients diagnosed as having chronic hepatitis C, confirmed by PCR (HCV RNA) and liver biopsy, were treated with interferon alpha 2a or 2b for at least six months, and were follow...

Journal: :Hepatology 2009
Robert Perrillo

UNLABELLED Alpha interferon is the only licensed drug for hepatitis B with immunomodulatory as well as viral inhibitory properties. Potential advantages of interferon compared to nucleoside analogs include a lack of drug resistance, a finite and defined treatment course, and a higher likelihood for hepatitis B surface antigen (HBsAg) clearance. Approximately 30% of hepatitis B e antigen (HBeAg)...

2004

The current standard of treatment for hepatitis C virus (HCV) is a combination of two drugs: pegylated interferon and ribavirin. The virological response rate, treatment duration, and ribavirin dose vary according to several prognostic factors: genotype, baseline HCV RNA (viral load), race, body weight, age, and liver histology. In one study, 48 weeks of pegylated interferon plus ribavirin led ...

Journal: :Minerva medica 2009
F Bihl F Negro

Treatment for chronic hepatitis C has changed over the past years achieving higher response rates. The combination treatment with pegylated interferon-a and ribavirin is tailored based on the on-treatment virological responses. With this response-guided therapy, the overall sustained virological response rate is about 55%. Many new antivirals are currently under investigation and some will be c...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید